GlaxoSmithKline ( GlaxoSmithKline )

GlaxoSmithKline

GlaxoSmithKline's picture

About GlaxoSmithKline

GlaxoSmithKline started operations on 1 January 2001 following the merger of GlaxoWellcome plc and SmithKline Beecham plc, but our combined histories go back much further than that. Find out about the many products and mergers that led to the GSK we know today.

GlaxoSmithKline press release, blog etc

11/15/2018 - 20:29 ViiV Healthcare receives CHMP Positive Opinion for Tivicay EU label update with GEMINI study data for the 2-drug regimen of Tivicay + lamivudine
11/08/2018 - 22:10 Once-daily Trelegy Ellipta gains expanded COPD indication in Europe
11/07/2018 - 21:23 Statement: GSK supports GOLD committees efforts to further personalise COPD management
10/31/2018 - 13:22 ViiV Healthcare announces positive phase 3 results from the BRIGHTE study of fostemsavir at 48 weeks in heavily treatment-experienced patients with HIV
10/30/2018 - 13:46 ViiV Healthcare reports positive 48-week results for second phase III study for novel, long-acting, injectable HIV-treatment regimen
10/29/2018 - 10:59 ViiV Healthcare presents three-year data for investigational long-acting injectable, two-drug HIV regimen
10/29/2018 - 10:31 GSK announces positive phase 3 results for daprodustat in patients with anaemia associated with chronic kidney disease
10/20/2018 - 21:39 GSK presents new efficacy and safety data of an anti GM-CSF antibody in patients with rheumatoid arthritis
10/18/2018 - 15:47 ViiV Healthcare submits New Drug Application to US FDA for single-tablet, two-drug regimen of dolutegravir and lamivudine for treatment of HIV
10/02/2018 - 11:06 Positive results from Harmony Outcomes study of albiglutide published in The Lancet
09/21/2018 - 12:17 Kozenis (tafenoquine) approved by the Australian Therapeutic Goods Administration for the radical cure of P. vivax malaria
09/21/2018 - 09:52 GSK and Tres Cantos Open Lab Foundation announce additional 5m funding for open innovation research in diseases impacting the developing world
09/21/2018 - 08:57 Trelegy Ellipta receives positive CHMP opinion supporting expanded COPD indication in Europe
09/14/2018 - 06:08 ViiV Healthcare submits regulatory application to European Medicines Agency for single-tablet, two-drug regimen of dolutegravir and lamivudine for treatment of HIV
09/10/2018 - 17:58 GSK data presented at ERS further supports its industry-leading respiratory medicines portfolio
09/10/2018 - 15:41 GSK announces results of indirect treatment comparisons of Nucala to benralizumab and reslizumab for severe eosinophilic asthma
09/07/2018 - 17:03 GSK receives complete response letter from US FDA for use of mepolizumab in COPD patients
08/30/2018 - 13:11 European Commission approves Nucala (mepolizumab) for the treatment of children with severe asthma